Regulus Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RGLS and other ETFs, options, and stocks.

About RGLS

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. 

CEO
Joseph P. Hagan
CEOJoseph P. Hagan
Employees
30
Employees30
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2007
Founded2007
Employees
30
Employees30

RGLS Key Statistics

Market cap
172.83M
Market cap172.83M
Price-Earnings ratio
-1.67
Price-Earnings ratio-1.67
Dividend yield
—
Dividend yield—
Average volume
275.17K
Average volume275.17K
High today
$2.87
High today$2.87
Low today
$2.61
Low today$2.61
Open price
$2.83
Open price$2.83
Volume
406.15K
Volume406.15K
52 Week high
$3.79
52 Week high$3.79
52 Week low
$1.08
52 Week low$1.08

RGLS News

Yahoo Finance 4d
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series - Yahoo Finance

SAN DIEGO, April 30, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inno...

Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series - Yahoo Finance
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.